Erratum to: phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis -KOGC04-
© Matsuda et al.; licensee BioMed Central Ltd. 2014
Received: 16 June 2014
Accepted: 16 June 2014
Published: 25 June 2014
In the “Chemoradiotherapy” section in the Methods, the 1st and 3rd paragraphs should read as follows:
“The chemoradiotherapy protocol consisted of administration of S-1 plus biweekly cisplatin and radiation (Figure 1). The initial chemoradiotherapy schedule was for 6 weeks: S-1 was orally administered twice daily from the evening of day 1 to the morning of day 15, and the total dose was based on the patient’s body surface area (BSA), as follows: <1.25 m2, 80 mg; 1.25–1.5 m2, 100 mg; and >1.5 m2, 120 mg. An escalating dose of cisplatin was administered by infusion over 1 h on days 1 and 15 without infusional hydration. The starting dose (level 1) of cisplatin was 15 mg/m2, the second dose (level 2) was 20 mg/m2, and the third dose (level 3) was 25 mg/m2.”
“After initial chemoradiotherapy, one cycle of combination chemotherapy with S-1 plus biweekly cisplatin was delivered. This consisted of 42 days of S-1 administered from the evening of day 1 to the morning of day 29 and of cisplatin administered on days 1, 15, and 29.”In “Figure 1,” based on the description in the manuscript, the duration of S-1 treatment in the initial chemoradiotherapy was revised to 1–15 days from 1–22 days (Figure 1).
- Matsuda S, Takahashi T, Fukada J, Fukuda K, Kawakubo H, Saikawa Y, Kawaguchi O, Takeuchi H, Shigematsu N, Kitagawa Y: Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04. Radiat Oncol. 2014, 9: 9-10.1186/1748-717X-9-9.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.